NT219 Plus Cetuximab Elicits Responses, Demonstrates Tolerability in Recurrent or Metastatic HNSCC
Second-line treatment with NT219 alone and in combination with cetuximab demonstrated safety and tolerability, and the combination produced confirmed partial responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.